ABSTRACT
We determined CR1, CD35 the C3b, C4b receptor density, C3b/C3bi and C4d deposits densities on Erythrocytes (E) in 51 COVID-19 patients undergoing O2 therapy or assisted ventilation in ICU units in Rheims France. A clear acquired decrease of CR1 density of E from COVID-19 patients was observed, particularly among fatal cases, and paralleling several severity parameters.
Deposits of C4d largely above values observed in normal individuals, mostly without C3 deposits, have been observed in more than 80% of the patients, reminiscent of the sub endothelial pericapillary deposits in organ transplant rejection, already observed on E in parallel, as well as also observed on E in clinical SLE flares.
Conversely, significant C3 deposits were only observed among ¼ of the patients. The decrease of CR1/E density, and the detection of virus spike, C3 or C4 fragment on E, among COVID-19 patients, are likely to be two aspects of the same phenomenon of immune complexes or complement fragment coated cell debris handling and clearance.
Measurement of C4d deposit on E might represent a way for assessing inflammation and complement activation occurring in organ capillaries. CR1/E decrease might represent a cumulative index of complement activation in COVID-19 patients.
Taken together, these original findings stress on the participation of the complement regulatory proteins in that disease and evidence that E matter in immune mechanisms in COVID-19 patients.
The use of CR1, or CR1-like molecules with the aim of down regulating complement activation and inflammation for therapy should also be considered.
HIGHLIGHTS
Acquired decrease of CR1 on E in COVID-19 patients, particularly among fatal cases, and paralleling several severity parameters.
Large C4d deposits on E in most patients, reminiscent of the pericapillary deposits in organ transplant rejection, already observed on E in parallel, as well as on E from SLE flares.
C4d deposit on E, a possible way for assessing inflammation and complement activation in organ capillaries.
Decreased CR1/E, a possible cumulative index of complement activation in COVID-19 patients.
The use of CR1 or CR1-like molecules for down regulating complement activation for therapy should also be considered.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Partial Funding by the Not-for-profit Organisation "Association pour le Developement de l'Immunologie et de la Microbiologie Remoise" ADMIR Grant 2020/0001.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Rheims University Hospital has obtained the authorization to create plasma and serum libraries from the Human Protection Committee (CPP Est III, national number: 2020-A01093-36) in order to study the soluble Vascular Endothelial Growth Factor (sFlt-1) receptor in intensive care patients with severe COVID-19 pneumonitis. The patients or their families signed an informed consent form to participate, specifying that other elements, such as the red blood cells, that were to be discarded, could be used for research for other purposes, in the context of the COVID-19 epidemic. Blood donors were healthy volunteers who signed the general informed consent from the national Etablissement Francais du Sang (EFS). Aged patients were from a cohort with individual informed consents approved by the regional ethics committee (CPP Est II), under the protocol number 2011-A00594-37.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
We can provide upon request from researchers fresh reference E without charge for the calibration curve of Flow Cytometry measurement of CR1/E. As well as assistance for setting-up methologies used from the corresponding Author.
